Tests eloralintide against placebo in adults with overweight or obesity
Compares eloralintide with placebo in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
Key facts
- Where
- Neuss, GermanySee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07665879, who can take part
Where in Germany
- PROFIL Institut fuer Stoffwechselforschung GmbHNeuss, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07665879EU 2025-523873-41-00
- Record updated
- 16 July 2026
- Original description
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.Read full original descriptionShow less
A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
Inclusion: Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%); Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²); Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening; Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.
Exclusion: Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a significant extent; Have a prior or planned surgical treatment for obesity. Exceptions: The following are allowed if they occurred more than 1 year before screening:; liposuction; cryolipolysis, or; abdominoplasty; Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of gestational diabetes are eligible to participate in this study; Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis; Are unwilling to comply with the lifestyle and dietary restrictions required for this study; Are individuals AFAB who are lactating; Are individuals AFAB who are pregnant or intend to become pregnant or to breastfeed during the study, or individuals AMAB who intend to conceive a pregnancy during the study.